On some of the cancer signaling pathways (i.e., MEK/MAPK/Erk, PI3K/Akt/mTor, NF-κB, and p53), core genes (i.e., MAP2K7, PIK3C2A, PIK3CD, PIK3CB, TNFSF9, TNFSF14, NRAS, GSK3B, Notch3, TP53TG5 and SNAI1) experienced copy-number changes during different phases of treatment. This evidence concerns the gene GSK3B and cancer.